Related Industry Reports:
- The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution?
- Colorectal Cancer - Shaping the future dynamics of colorectal cancer management
- Pipeline Insight: Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline Targeted Therapi
Macrophage migration inhibitory factor in cancer.
Cancer investigation 2007 Dec 1; 25(8):715-9
Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F, Dalay N
Department of Basic Oncology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. yasasever@yahoo.com
The objective of this study was to investigate the expression of macrophage migration inhibitory factor (MIF) in patients with colorectal cancer (GIS) and malignant melanoma (MM). The study group consists of pathologically verified colorectal cancer (n = 63) and malignant melanoma (n = 65) patients and healthy controls (n = 25). Serum MIF concentrations were determined by enzyme-linked immunosorbent assay. Serum values of the patients were significantly higher than the controls (p < 0.001 for GIS, p = 0.032 for MM). Diagnostic sensitivity and specificity were calculated for MIF for colorectal and malignant melanoma. The results demonstrate that colorectal cancer express and secrete large amounts of MIF.
Keywords: MIF colorectal cancer